Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report

…, E Wieland, JB Woillard, MJ Barten… - Therapeutic drug …, 2019 - journals.lww.com
Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

T van Gelder, J Klupp, MJ Barten… - Therapeutic drug …, 2001 - journals.lww.com
Mycophenolate mofetil (MMF) is almost completely absorbed from the gut and is rapidly de-esterified
into its active drug, mycophenolic acid (MPA). The main metabolite is …

Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology

…, JB Woillard, TC Zwart, MJ Barten… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Therapeutic drug monitoring of everolimus: a consensus report

…, M Brunet, K Budde, MJ Barten… - Therapeutic drug …, 2016 - journals.lww.com
In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …

[HTML][HTML] COVID-19 among heart transplant recipients in Germany: a multicenter survey

…, A Rieth, M Berchtold-Herz, MJ Barten… - Clinical Research in …, 2020 - Springer
Aims Heart transplantation may represent a particular risk factor for severe coronavirus
infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent …

Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation

…, U Christians, M López-Hoyos, MJ Barten… - Therapeutic drug …, 2016 - journals.lww.com
With current treatment regimens, a relatively high proportion of transplant recipients experience
underimmunosuppression or overimmunosuppression. Recently, several promising …

[HTML][HTML] Current trends in implantable left ventricular assist devices

J Garbade, HB Bittner, MJ Barten… - Cardiology research and …, 2011 - hindawi.com
The shortage of appropriate donor organs and the expanding pool of patients waiting for
heart transplantation have led to growing interest in alternative strategies, particularly in …

The clinical impact of donor-specific antibodies in heart transplantation

MJ Barten, U Schulz, A Beiras-Fernandez… - Transplantation …, 2018 - Elsevier
Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection
(AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac …

Outcome of patients suffering from acute type B aortic dissection: a retrospective single-centre analysis of 135 consecutive patients

…, M Jenniches, MA Borger, MJ Barten… - European journal of …, 2010 - academic.oup.com
Objectives: Acute uncomplicated Stanford type B aortic dissection (TBAD) is optimally
managed with medical treatment. However, surgery and thoracic endovascular aortic repair (…

Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: de-escalate and ambulate

…, E Lubos, H Grahn, M Rybczinski, MJ Barten… - Journal of Critical …, 2020 - Elsevier
Purpose Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) stabilizes patients
in refractory cardiogenic shock. However, ECMO-related complications strongly affect the …